1872: Foundation of Hausmann’s pharmacy
The pharmacist Caspar Friedrich Hausmann founded a pharmacy in St. Gallen.
The pharmacist Caspar Friedrich Hausmann founded a pharmacy in St. Gallen.
Hausmann Laboratories Inc. was founded in St. Gallen. The product Ferrum Hausmann I.V. was introduced in Switzerland.
Galenica diversified into new areas setting up the new subsidiary Panpharma Ltd. (later Vifor Ltd.).
Iron (III) polymaltose complex (Ferrum Hausmann I.M. & oral) was introduced in the market.
Galenica acquired the manufacturing companies Vifor Ltd. and Cooper Ltd., which operated in the areas of hospital supplies and pharmaceutical products.
Maltofer® (iron (III) polymaltose complex standardised) was registered and introduced in the market.
Hausmann Laboratories Inc. was acquired by Galenica. The company specialised in perfusions, sterile solutions and iron products.
The activities in pharmaceutical specialties of the former Hausmann Laboratories Inc. led to the foundation of Vifor (International) Ltd.
Considerable investments were made to develop new products for Vifor Ltd. to support the company’s internationalisation.
The acquisition of Medichemie Group strengthened Galenica's position in the Swiss healthcare market with its herbal remedies and gastroenterological products.
In November, 2001 the FDA (US Food and Drug Administration) approved intravenous iron for the treatment of haemodialysis-dependent CKD patients in the US market.
Galenica acquired Potter's (Herbal Supplies) Ltd.
Aspreva (acquired by Galenica in 2008) entered into an exclusive collaboration agreement with Roche for the worldwide (excluding Japan) development and commercialisation of CellCept®.
Galenica acquired the brand Perskindol® from Pharma Singer Ltd. Today, Perskindol® is one of the best-selling over-the-counter products of Vifor Pharma.
Vifor (International) Ltd. signed a long-term cooperation agreement with Luitpold Pharmaceuticals, Inc. and its subsidiary American Regent, Inc. to market existing and future iron products in the USA.
Vifor Pharma acquired Equazen Nutraceuticals Limited with its leading product eye q™ in 2006.
The registration files for the new iron-based product Ferinject® (ferric carboxymaltose) were submitted in Switzerland and in 18 countries of the EU in 2006 and approved in 2007.
In November 2007, Ferinject® (ferric carboxymaltose) was launched in Germany.
The new Vifor Pharma was created through the acquisition of the former Aspreva Pharmaceutical Corporation.
Vifor Pharma and Fresenius Medical Care, the world’s largest provider of dialysis products and services, entered into exclusive license agreements for Venofer® and Ferinject®.
By the end of 2008 Ferinject® (ferric carboxymaltose) was launched in Switzerland and eight other market.
With the acquisition of 51% of Sweden’s Renapharma, a company specialised in the sale of medicines for iron deficiency therapy, Vifor Pharma further strengthened its presence in key European markets.
Vifor Pharma entered into an agreement with Syner-Med Pharmaceutical Products (SMPP), its longstanding partner in the UK and Ireland.
In France Vifor Pharma established its own marketing and sales organisation.
Equazen eye q™ was introduced to the Swiss market under the name Equazen IQ™.
In September 2009 Galenica acquired OM Pharma, a fully integrated specialty biotechnology and pharmaceutical Swiss company with unique expertise in the field of immunology.
In October 2009 Vifor Pharma reached an important milestone in its clinical development program.
As part of its strategy to build its presence in key European markets, Vifor Pharma established three new affiliates: in Austria, The Netherlands and Spain.
Another important milestone was reached with the launch of Ferinject® (ferric carboxymaltose) in Spain.
In January 2010 Vifor Pharma UK took over the intravenous iron business from its UK distributor Syner-Med, creating its own independent sales, medical and marketing infrastructure based in Bagshot, Surrey.
In June 2010, Vifor Pharma announced a partnership with Fresenius Medical Care (FMC) in which FMC agreed to support a study for a phosphate binder in the US and become the commercial partner in North America.
In September 2010 Vifor Pharma entered into a partnership with Kissei Pharmaceuticals Co. Ltd. for the development and commercialisation of a phosphate binder in Japan.
In December 2010 Vifor Pharma and Fresenius Medical Care announced an extension of their partnership through the creation of a specialty pharma company.
By the end of 2010 Ferinject® (ferric carboxymaltose) was registered in 32 and launched in 16 countries.
Vifor Pharma established three new affiliates: in Australia, Belgium and Romania.
In July 2011 the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK approved a new dosage regimen for intravenous iron (ferric carboxymaltose).
In August 2011 Vifor Pharma and Hikma Pharmaceuticals Ltd. (Hikma) entered into an agreement under which Hikma will market Ferinject® (ferric carboxymaltose) in the Middle East and North Africa region (MENA).
In October 2011 the US partner Luitpold Pharmaceuticals, Inc. submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Injectafer® (US brand name of Ferinject®).
In October 2011 the common company of Galenica and Fresenius Medical Care – Vifor Fresenius Medical Care Renal Pharma Ltd. (Vifor FMC Renal Pharma) – received approval from the European and Swiss antitrust authorities.
In November 2011 Galenica announced the acquisition of all shares of Vifor Pharma Uriach SL, a joint venture with its Spanish partner Grupo Uriach, as well as Uriach’s Primary Care Business.
By the end of 2011 Ferinject® (ferric carboxymaltose) was registered in 38 and launched in 27 countries.
In April 2012 the results of the PREFER study were reported and showed that a single 1,000 mg dose of intravenous iron (ferric carboxymaltose) rapidly improves fatigue in symptomatic iron deficient, non-anaemic women.1
In May 2012 Debiopharm Group™ and Vifor Pharma announced the signing of an exclusive agreement covering the distribution and commercialization in Switzerland of two medications.
In July 2012 the pivotal phase III clinical study showed that a new phosphate binder successfully controls hyperphosphatemia in patients with chronic kidney disease on dialysis.
Vifor Pharma established a new affiliate in Italy in July 2012.
In September 2012 the US partner Luitpold Pharmaceuticals, Inc., received US Food and Drug Administration (FDA) approval for use of intravenous iron in paediatric patients.
In December 2012 the first approval dossier of the new phosphate binder was sent for submission to the European Medicines Agency (EMA) to seek approval in the EU.
By the end of 2012 Ferinject® (ferric carboxymaltose) was registered in 43 countries worldwide and had been launched in 35 markets.
Vifor Pharma entered into an exclusive distribution agreement with China Medical System Holdings Limited (CMS) – a leading Chinese pharmaceutical company – for the Vifor Pharma products Maltofer® and Uro-Vaxom®.
The application for the authorisation of the new phosphate binder has been submitted to the US Food and Drug Administration (FDA), the Swiss Agency for Therapeutic Products (Swissmedic) and to the authorities in Singapore.
Helsinn Healthcare SA and Vifor Pharma entered into an exclusive license and distribution agreement for netupitant-palonosetron fixed dose combination.
The FIND-CKD results demonstrate that intravenous iron (ferric carboxymaltose) reduces or delays requirement for alternative anaemia management compared with oral iron therapy.
Ferinject® (US brand name Injectafer®) receives the US Food and Drug Administration (FDA) approval for the treatment of Iron Deficiency Anaemia (IDA).
Vifor Pharma entered into an exclusive licensing agreement with Zeria Pharmaceutical Co., Ltd. for the development and commercialization of Ferinject® (ferric carboxymaltose) in Japan.
The new phosphate binder (sucroferric oxyhydroxide) receives US FDA approval for the treatment of hyperphosphatemia in Chronic Kidney Disease Patients on dialysis.
By the end of 2013 Ferinject® (ferric carboxymaltose) was registered in 58 countries worldwide and had been launched in 41 markets.
IronDeficiency.com, a new global website, was launched by Vifor Pharma with the aim of raising awareness about iron deficiency amongst healthcare professionals, patients and the general public around the world.
Since June 2014 Ferinject® (ferric carboxymaltose) is listed on the Pharmaceutical Benefits Scheme (PBS) in Australia and since August 2014 it is listed on the Hospital Medicines List in New Zealand.
Galenica lays foundation for Vifor Pharma to become a successful stand-alone global specialty pharma company within 3 to 5 years.
Velphoro® (sucroferric oxyhydroxide) received EU marketing authorisation from the European Commission.
CONFIRM-HF demonstrated that Ferinject® improves exercise capacity in patients with Chronic Heart Failure (CHF) and also confirmed the efficacy and safety profile of Ferinject® observed in the FAIR-HF study.
By the end of 2014 Ferinject® (ferric carboxymaltose) was registered in 63 countries worldwide and had been launched in 54 markets.
Velphoro® (polynuclear iron(III)-oxyhydroxide, sucroferric oxyhydroxide) received Swissmedic approval.
Galenica and Roche entered into an exclusive license agreement for the commercialisation of Roche’s drug Mircera® in the US and Puerto Rico.
VFMCRP expanded its product portfolio and established eight affiliates in some of Europe’s most important markets with a sales, marketing and medical organisation dedicated to renal pharmaceuticals.
Vifor Fresenius Medical Care Renal Pharma and Relypsa entered into a partnership to commercialise the oral potassium binder Patiromer FOS in Europe and additional territories.
A meta-analysis reported that Ferinject® treatment of iron deficiency in patients with systolic chronic heart failure is associated with reduced rates of cardiovascular hospitalisations and cardiovascular deaths.
P-TOL® (sucroferric oxyhydroxide) received approval by the Ministry of Health, Labour and Welfare in Japan for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.
Soho Flordis International (SFI), through its Swiss subsidiary Ginsana SA, acquired Potters and the Equazen™ brand portfolio from Vifor Pharma.
Swissmedic approved Akynzeo® (netupitant/palonosetron) for use in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Switzerland.
By the end of 2015 Ferinject® (ferric carboxymaltose) was registered in 69 countries worldwide and had been launched in 61 markets.